In contrast, substances that showed great potential in treating PSP such as salsalate (an NSAID that targets acetyltransferase p300 and inhibits tau acetylation) (Min et al., 2015; US National Library of Medicine, 2015–2018), and plasma infusion did not provide significant therapeutic benefits (VandeVrede et al., 2020). This evidence concerns the gene MAPT and supranuclear palsy, progressive, 1.